Cellectis (CLLS) EBITDA Margin (2015 - 2026)
Cellectis' EBITDA Margin came in at -365.44% for Q2 2026, down 338.12 percentage points from -27.32% a year earlier and down 8.30 percentage points from the prior quarter.
Powered by 
Analysis
Cellectis (CLLS) EBITDA Margin (2015 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Cellectis reported EBITDA Margin of -66.12%, down 22.21 percentage points year-over-year; for FY2025, it came in at -17.84%, up 77.83 percentage points from FY2024.
- EBITDA Margin carries a five-year change of +136.33 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was -95.67% in FY2024 (+10338.63 pp), -10434.30% in FY2023 (-10062.75 pp), -371.56% in FY2022 (-77.21 pp) and -294.35% in FY2021 (-140.18 pp).
- The Q2 2026 figure represents the lowest quarterly EBITDA Margin since Q4 2023.
- Year-over-year, EBITDA Margin has declined for three consecutive quarters, with an average year-over-year change of +2351.16 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q1 2024 (a gain of 13290.54 percentage points), and the weakest in Q3 2022 (a drop of 12712.51 percentage points).
- Business Quant data shows CLLS's EBITDA Margin at -357.14% (Q1 2026), -96.33% (Q4 2025) and 37.11% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Cellectis | 111.38 Mn | -642.02 Mn | - | -365.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -365.44% |
| Mar 31, 2026 | -357.14% |
| Dec 31, 2025 | -96.33% |
| Sep 30, 2025 | 37.11% |
| Jun 30, 2025 | -27.32% |
| Mar 31, 2025 | -86.79% |
| Dec 31, 2024 | -38.15% |
| Sep 30, 2024 | -37.34% |
| Jun 30, 2024 | -154.86% |
| Mar 31, 2024 | -360.53% |
| Dec 31, 2023 | -8,620.85% |
| Sep 30, 2023 | -10,454.84% |
| Jun 30, 2023 | -10,787.64% |
| Mar 31, 2023 | -13,651.08% |
| Dec 31, 2022 | -5.82% |
| Sep 30, 2022 | -13,169.71% |
| Jun 30, 2022 | -1,698.93% |
| Mar 31, 2022 | -1,461.08% |
| Dec 31, 2021 | -213.82% |
| Sep 30, 2021 | -457.21% |
API Access
Cellectis EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CLLS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CLLS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CLLS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();